EP2771002A4 - Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydromorphone, prodrugs, methods of making and use thereof - Google Patents

Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydromorphone, prodrugs, methods of making and use thereof

Info

Publication number
EP2771002A4
EP2771002A4 EP12843820.7A EP12843820A EP2771002A4 EP 2771002 A4 EP2771002 A4 EP 2771002A4 EP 12843820 A EP12843820 A EP 12843820A EP 2771002 A4 EP2771002 A4 EP 2771002A4
Authority
EP
European Patent Office
Prior art keywords
benzoic acid
hydromorphone
prodrugs
making
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP12843820.7A
Other languages
German (de)
French (fr)
Other versions
EP2771002A1 (en
Inventor
Travis Mickle
Sven Guenther
Guochen Chi
Jaroslaw Kanski
Andrea K Martin
Bindu Bera
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zevra Therapeutics Inc
Original Assignee
KemPharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by KemPharm Inc filed Critical KemPharm Inc
Publication of EP2771002A1 publication Critical patent/EP2771002A1/en
Publication of EP2771002A4 publication Critical patent/EP2771002A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
EP12843820.7A 2011-10-26 2012-10-25 Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydromorphone, prodrugs, methods of making and use thereof Withdrawn EP2771002A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161551600P 2011-10-26 2011-10-26
US201261657201P 2012-06-08 2012-06-08
PCT/US2012/061813 WO2013063204A1 (en) 2011-10-26 2012-10-25 Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydromorphone, prodrugs, methods of making and use thereof

Publications (2)

Publication Number Publication Date
EP2771002A1 EP2771002A1 (en) 2014-09-03
EP2771002A4 true EP2771002A4 (en) 2015-08-12

Family

ID=48168468

Family Applications (1)

Application Number Title Priority Date Filing Date
EP12843820.7A Withdrawn EP2771002A4 (en) 2011-10-26 2012-10-25 Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydromorphone, prodrugs, methods of making and use thereof

Country Status (19)

Country Link
US (6) US8816083B2 (en)
EP (1) EP2771002A4 (en)
JP (1) JP5769889B2 (en)
KR (1) KR101589846B1 (en)
CN (2) CN104136031B (en)
AR (1) AR088551A1 (en)
AU (1) AU2012328837B2 (en)
BR (1) BR112014010099A8 (en)
CA (1) CA2856608C (en)
CL (1) CL2014000995A1 (en)
CO (1) CO7010825A2 (en)
HK (2) HK1197191A1 (en)
IL (1) IL231822A0 (en)
IN (1) IN2014DN03009A (en)
MX (1) MX362857B (en)
RU (1) RU2573388C2 (en)
SG (1) SG11201401856VA (en)
WO (1) WO2013063204A1 (en)
ZA (1) ZA201402339B (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10849981B2 (en) 2009-07-02 2020-12-01 KemPham, Inc. Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydrocodone, prodrugs, methods of making and use thereof
UA102916C2 (en) 2009-07-02 2013-08-27 Кемфарм, Інк. Composition based on conjugates of hydrocodone with benzoic acid, benzoic acid or heteroaryl carboxylic acid derivatives, prodrugs and method for treatment of abuses
RU2573388C2 (en) * 2011-10-26 2016-01-20 Кемфарм Инк. Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydromorphone, prodrugs, methods for producing and using them
CA2932477C (en) 2013-12-06 2023-10-10 Baikang (Suzhou) Co., Ltd Bioreversable promoieties for nitrogen-containing and hydroxyl-containing drugs
GB201417529D0 (en) 2014-10-03 2014-11-19 Isis Innovation Beta lactamase inhibitors
NZ731591A (en) 2014-11-25 2018-06-29 Kempharm Inc Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of oxycodone
MX2017006935A (en) * 2014-12-02 2017-08-10 Kempharm Inc * Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of oxymorphone, prodrugs, methods and making and use thereof.
US10449190B2 (en) 2015-04-27 2019-10-22 John K. Thottathil Alpha-hydroxy carboxylic acid and derivatives and other GRAS-based prodrugs of opioids and uses thereof
US10017519B2 (en) 2015-04-27 2018-07-10 3St Research Llc Alpha-hydroxy carboxylic acid and derivatives and other GRAS based prodrugs of oxycodone and uses thereof
US9987269B2 (en) 2015-04-27 2018-06-05 3St Research Llc Alpha-hydroxy carboxylic acid and derivatives and other GRAS-based prodrugs of oxymorphone and uses thereof
US10226456B2 (en) 2015-04-27 2019-03-12 3St Research Llc Methods and compositions for preventing opioid abuse
EP3210596A1 (en) 2016-02-29 2017-08-30 G.L. Pharma GmbH Abuse-deterrent pharmaceutical composition
EP3231420A1 (en) 2016-02-29 2017-10-18 G.L. Pharma GmbH Abuse-deterrent pharmaceutical compositions
EP3210630A1 (en) 2016-02-29 2017-08-30 G.L. Pharma GmbH Abuse-deterrent pharmaceutical compositions
WO2018071879A1 (en) * 2016-10-14 2018-04-19 Kempharm, Inc. Immediate-release abuse deterrent compositions or medicaments for treating pain, add, adhd and other syndromes or disorders
IL277071B1 (en) 2018-03-08 2024-03-01 Incyte Corp AMINOPYRAZINE DIOL COMPOUNDS AS PI3K-y INHIBITORS
US11046658B2 (en) 2018-07-02 2021-06-29 Incyte Corporation Aminopyrazine derivatives as PI3K-γ inhibitors
WO2021097532A1 (en) * 2019-11-22 2021-05-27 Deakin University Organic corrosion inhibitors
WO2021097531A1 (en) * 2019-11-22 2021-05-27 Deakin University Polyionic corrosion inhibitors

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6150524A (en) * 1995-12-20 2000-11-21 Cenes Ltd. Morphine derivatives with analgesic activity
WO2003011881A2 (en) * 2001-07-27 2003-02-13 Euro-Celtique, S.A. Sugar derivatives of hydromorphone, dihydromorphine and dihydroisomorphine, compositions thereof and uses for treating or preventing pain
WO2008101202A1 (en) * 2007-02-16 2008-08-21 Pharmacofore, Inc. N-17-alkylated prodrugs of opioids
WO2011008636A1 (en) * 2009-07-15 2011-01-20 Mallinckrodt Inc. 3-oxy-hydromorphone derivatives

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4668685A (en) 1984-07-05 1987-05-26 E.I. Du Pont De Nemours And Company Substituted benzoate ester prodrug derivatives of 3-hydroxymorphinans, which are analgesics or narcotic antagonists
US5965161A (en) * 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
NZ298712A (en) * 1995-01-16 1998-12-23 Commw Scient Ind Res Org Fatty acid acyl group conjugates as therapeutic compounds
KR101476574B1 (en) 1999-10-29 2014-12-24 유로-셀티크 소시에떼 아노뉨 Controlled release hydrocodone formulations
BR0210179A (en) 2001-06-05 2004-04-27 Control Delivery Sys Inc Sustained-release analgesic compounds
US7135575B2 (en) 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
WO2004082620A2 (en) 2003-03-13 2004-09-30 Controlled Chemicals, Inc. Oxycodone conjugates with lower the abuse potential and extended duration of action
CA2540678C (en) 2003-09-30 2011-02-22 New River Pharmaceuticals Inc. Pharmaceutical compositions for prevention of overdose or abuse
US7661226B2 (en) * 2005-01-11 2010-02-16 Larson Manufacturing Company Installation method for a storm door
EP2007389A2 (en) * 2006-04-14 2008-12-31 Shire LLC Compositions and methods for enhancing analgesic potency of covalently bound compounds, attenuating its adverse side effects, and preventing their abuse
MX2008014794A (en) 2006-05-26 2009-04-08 Pharmacofore Inc Controlled release of phenolic opioids.
WO2008055230A2 (en) 2006-10-31 2008-05-08 Rebit, Inc. Automatically shadowing data for a plurality of network-connected computers using a network-attached memory
US20090186832A1 (en) 2008-01-18 2009-07-23 Shire Llc Amino acid peptide pro-drugs of phenolic analgesics and uses thereof
JP2013523599A (en) 2009-04-02 2013-06-17 シャイア エルエルシー Novel opioid dicarboxylic acid linked amino acid and peptide prodrugs and uses thereof
AU2010266209B2 (en) * 2009-07-02 2013-09-26 Kempharm, Inc. Phenylethanoic acid, phenylpropanoic acid and phenylpropenoic acid conjugates and prodrugs of hydrocodone, methods of making and use thereof
UA102916C2 (en) 2009-07-02 2013-08-27 Кемфарм, Інк. Composition based on conjugates of hydrocodone with benzoic acid, benzoic acid or heteroaryl carboxylic acid derivatives, prodrugs and method for treatment of abuses
CA2768236C (en) 2009-07-16 2018-05-22 Mallinckrodt Llc (+)-morphinans as antagonists of toll-like receptor 9 and therapeutic uses thereof
WO2011031350A1 (en) 2009-09-08 2011-03-17 Pharmacofore, Inc. Compositions comprising enzyme-cleavable ketone-modified opioid prodrugs and optional inhibitors thereof
CA2768199C (en) 2010-07-16 2018-08-28 Mallinckrodt Llc (+)-morphinans as antagonists of toll-like receptor 9 and therapeutic uses thereof
US8685916B2 (en) 2011-03-09 2014-04-01 Signature Therapeutics, Inc. Opioid prodrugs with heterocyclic linkers
RU2573388C2 (en) 2011-10-26 2016-01-20 Кемфарм Инк. Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydromorphone, prodrugs, methods for producing and using them

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6150524A (en) * 1995-12-20 2000-11-21 Cenes Ltd. Morphine derivatives with analgesic activity
WO2003011881A2 (en) * 2001-07-27 2003-02-13 Euro-Celtique, S.A. Sugar derivatives of hydromorphone, dihydromorphine and dihydroisomorphine, compositions thereof and uses for treating or preventing pain
WO2008101202A1 (en) * 2007-02-16 2008-08-21 Pharmacofore, Inc. N-17-alkylated prodrugs of opioids
WO2011008636A1 (en) * 2009-07-15 2011-01-20 Mallinckrodt Inc. 3-oxy-hydromorphone derivatives

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2013063204A1 *

Also Published As

Publication number Publication date
US20190192670A1 (en) 2019-06-27
JP2014532651A (en) 2014-12-08
CN105749294A (en) 2016-07-13
US20170143839A1 (en) 2017-05-25
BR112014010099A2 (en) 2017-06-27
MX362857B (en) 2019-02-20
IL231822A0 (en) 2014-05-28
CA2856608A1 (en) 2013-05-02
MX2014004691A (en) 2014-07-09
SG11201401856VA (en) 2014-05-29
US10258696B2 (en) 2019-04-16
RU2014121065A (en) 2015-12-10
RU2573388C2 (en) 2016-01-20
US9566343B2 (en) 2017-02-14
ZA201402339B (en) 2015-07-29
WO2013063204A1 (en) 2013-05-02
AR088551A1 (en) 2014-06-18
CO7010825A2 (en) 2014-07-31
US10064956B2 (en) 2018-09-04
US20180064820A1 (en) 2018-03-08
US8816083B2 (en) 2014-08-26
HK1197191A1 (en) 2015-01-09
KR20140089520A (en) 2014-07-15
HK1223279A1 (en) 2017-07-28
EP2771002A1 (en) 2014-09-03
CA2856608C (en) 2017-05-16
US20180339056A1 (en) 2018-11-29
CN104136031A (en) 2014-11-05
CN104136031B (en) 2016-05-04
US9849185B2 (en) 2017-12-26
JP5769889B2 (en) 2015-08-26
NZ623106A (en) 2015-06-26
AU2012328837A1 (en) 2014-05-01
IN2014DN03009A (en) 2015-05-08
BR112014010099A8 (en) 2018-01-16
AU2012328837B2 (en) 2015-07-09
US20130150395A1 (en) 2013-06-13
CL2014000995A1 (en) 2014-07-25
US20140330021A1 (en) 2014-11-06
KR101589846B1 (en) 2016-01-28
US10441661B2 (en) 2019-10-15

Similar Documents

Publication Publication Date Title
HK1223279A1 (en) Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydromorphone, prodrugs, methods of making and use thereof
IL259889A (en) Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydrocodone, prodrugs, methods of making and use thereof
ZA201308086B (en) Derivatives of 1-anino-2-cyclopropylboronic acid
HK1211295A1 (en) C17-heteroaryl derivatives of oleanolic acid and methods of use thereof c17-
EP2798063A4 (en) Production of dihydrosterculic acid and derivatives thereof
HK1225714A1 (en) 3-heteroaroylamino-propionic acid derivatives and their use as pharmaceuticals
IL249825A0 (en) Substituted 3-heteroaroylamino-propionic acid derivatives and their use as pharmaceuticals
HK1244209A1 (en) Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of oxymorphone, prodrugs, methods and making and use thereof
EP2782902A4 (en) Derivatives of phenoxyisobutyric acid
HK1209727A1 (en) Preparation process of carboxylic acid derivatives and intermediates thereof

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20140403

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1197191

Country of ref document: HK

DAX Request for extension of the european patent (deleted)
RA4 Supplementary search report drawn up and despatched (corrected)

Effective date: 20150710

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/485 20060101AFI20150706BHEP

Ipc: A61K 31/185 20060101ALI20150706BHEP

Ipc: A61K 31/616 20060101ALI20150706BHEP

Ipc: C07D 489/00 20060101ALI20150706BHEP

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: KEMPHARM, INC.

17Q First examination report despatched

Effective date: 20171206

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/185 20060101ALI20190516BHEP

Ipc: A61K 31/616 20060101ALI20190516BHEP

Ipc: A61K 47/55 20170101AFI20190516BHEP

Ipc: A61K 31/485 20060101ALI20190516BHEP

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 25/04 20060101ALI20190521BHEP

Ipc: A61K 31/485 20060101ALI20190521BHEP

Ipc: A61K 31/185 20060101ALI20190521BHEP

Ipc: A61K 47/55 20170101AFI20190521BHEP

Ipc: A61K 31/616 20060101ALI20190521BHEP

INTG Intention to grant announced

Effective date: 20190618

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20191029

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1197191

Country of ref document: HK